Skip to main content
Clinical Trials/NL-OMON49462
NL-OMON49462
Withdrawn
Not Applicable

Glycemic control in the intensive care unit assisted by Glycostat, a continuos central venous blood glucose measurement system with an algorithm giving advice on insulin infusion rate - Glycemic control in the ICU assisted by Glycostat

Medische Hulpmiddelen Industrie0 sites20 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Medische Hulpmiddelen Industrie
Enrollment
20
Status
Withdrawn
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Medische Hulpmiddelen Industrie

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • \* Male and Female subjects, age \* 18 years, \* 85 years
  • \* ICU patients (any type) with an Arrow 3 or 4 lumen central venous catheter in
  • place (CVC in situ not for study, but part of standard practice)
  • \* Clinical parameters (vital signs, medical history, and physical examination)
  • not clinically significant or unstable as determined by the principal
  • investigator.
  • \* Informed consent obtained before any activities related to the investigation

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • \* Known or suspected allergy to device material
  • \* Not eligible to receive IV insulin
  • \* ICU patients without Arrow 3 lumen or 4 lumen central venous catheter in place
  • \* Previous participation (defined as participation on Day 1\) in this trial.
  • \* Acute and/or severe chronic illness or history of any illness that, in the
  • opinion of the Investigator, might pose additional risk in applying the
  • Glycostat probe to the subject
  • \* Participation in another investigational study within 30 days prior to

Outcomes

Primary Outcomes

Not specified

Similar Trials